Expert Panel Delivers Harsh Verdict on Aducanumab, FDA Decision Due by March 7

A key US FDA advisory committee voted overwhelmingly against Biogen’s controversial Alzheimer’s treatment aducanumab on November 6, two days after the agency issued a briefing document that gave a strongly positive review of the drug. With the vote being non-binding,...read more